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Abstract
Background: The pyronaridine-artesunate combination is one of the most recent oral artemisinin-based
therapeutic combinations (ACTs) recommended for the treatment of uncomplicated P. falciparum malaria. The
emergence of P. falciparum resistance to artemisinin has recently developed in Southeast Asia. Little data are
available on the association between pyronaridine susceptibility and polymorphisms in genes involved in
antimalarial drug resistance. The objective of the present study was to investigate the association between ex vivo
responses to pyronaridine and the K76T mutation in the pfcrt gene in P. falciparum isolates.
Methods: The assessment of ex vivo susceptibility to pyronaridine was performed on 296 P. falciparum isolates
using a standard 42-h 3H-hypoxanthine uptake inhibition method. The K76T mutation was also investigated.
Results: The pyronaridine IC50 (inhibitory concentration 50 %) ranged from 0.55 to 80.0 nM. Ex vivo responses to
pyronaridine were significantly associated with the K76T mutation (p-value = 0.020). The reduced susceptibility to
pyronaridine, defined as IC50 > 60 nM, was significantly associated with the K76T mutation (p-value = 0.004). Using a
Bayesian mixture modelling approach, the pyronaridine IC50 were classified into three components: component A
(IC50 median 15.9 nM), component B (IC50 median 34.2 nM) and component C (IC50 median 63.3 nM). The K76T
mutation was represented in 46.3 % of the isolates in component A, 47.2 % of the isolates in component B and
73.3 % of the isolates in component C (p-value = 0.021).
Conclusion: These results showed the ex vivo reduced susceptibility to pyronaridine, i.e., IC50 > 60 nM, associated
with the K76T mutation.
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In 2002, the World Health Organization (WHO) recom-
mended the use of artemisinin-based combination ther-
apy (ACT) for the treatment of all cases of
uncomplicated malaria. The pyronaridine-artesunate
combination (Pyramax®) is one of the latest oral ACTs
recommended for the treatment of uncomplicated P.
falciparum and P. vivax malaria [1]. The combination
pyronaridine-artesunate has recently completed phase
III trials in humans. The safety and efficacy of this com-
pound were shown in four randomized clinical trials in
adults and children in Africa and Asia [2–5]. Pyronari-
dine-artesunate showed better efficacy compared with
mefloquine-artesunate for the treatment of uncomplicated
falciparum malaria in Cambodia and a non-inferior effi-
cacy compared with artemether-lumefantrine in Africa
and Southeast Asia. The emergence of P. falciparum re-
sistance to artemisinin and artemisinin derivatives has re-
cently developed in Southeast Asia, manifesting as delayed
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parasite clearance following treatment with artesunate
monotherapy or ACT [6, 7]. Resistance has still developed
with the most recent ACT in the form of
dihydroartemisinin-piperaquine, which demonstrated less
than 70 % efficacy [8, 9]. In areas where the resistance of
artemisinin is emerging, partner drugs are under increas-
ing pressure for the selection of resistance, and new thera-
peutics are limited. Thus, it is important to use an ACT in
which its partner drug shows a different mode of action or
mechanism of resistance. The in vitro responses to pyro-
naridine and piperaquine were differently distributed in a
triple normal distribution model for pyronaridine and a
quadruple normal distribution model for piperaquine [10].
Significant positive in vitro cross-susceptibility was ob-
served between pyronaridine and piperaquine (coefficient
of determination of 0.20–0.23) [11, 12]. In vitro and ex
vivo responses to piperaquine were not associated with
the K76T mutation in the P. falciparum chloroquine re-
sistance transporter gene (pfcrt) [13, 14]. Few data are
available on the association between pyronaridine suscep-
tibility and polymorphisms in the genes involved in anti-
malarial drug resistance. A study using 23 P. falciparum
strains showed that there was no significant association
between in vitro responses to pyronaridine and pfcrt poly-
morphism [15]. The objective of the present study was to
investigate the association between ex vivo responses to
pyronaridine and the K76T mutation in the pfcrt gene in
296 P. falciparum African isolates.
In total, 296 P. falciparum isolates were collected be-
tween April 2008 and August 2012 from patients hospi-
talized in France with imported malaria from African
malaria-endemic countries (Angola, Benin, Burkina Faso,
Cameroon, Central African Republic, Chad, Comoros,
Congo, Ivory Coast, Gabon, Gambia, Ghana, Guinea,
Madagascar, Mali, Mauritania, Mozambique, Niger,
Senegal, Togo, and Zambia). Informed consent was not
required for this study because the sampling and testing
procedures were conducted according to the French na-
tional recommendations for the care and surveillance of
malaria. The ex vivo responses to pyronaridine (Shin
Poong Pharm Co., Seoul, Korea) and chloroquine (St.
Louis, MO, USA) (control for pfcrt polymorphism) were
assessed as previously described using a standard 42-h
3H-hypoxanthine uptake inhibition method [10].
Batches of plates were tested and validated using the
chloroquine-susceptible 3D7 strain (West Africa) and
the chloroquine-resistant W2 strain (Indochina) (MR4,
Virginia, USA) in three to six independent experiments.
Nucleic acid extraction and pfcrt single-nucleotide poly-
morphism identification were previously described [14].
The pyronaridine IC50 values (inhibitory concentration
50 %) ranged from 0.55 to 80.0 nM (Fig. 1). The geomet-
ric mean was 20.8 ± 14.6 nM (standard deviation). Ex
vivo responses to pyronaridine were significantly
associated with the K76T mutation (p-value = 0.020),
and similar results were obtained for chloroquine IC50
(p-value < 0.001). Sixteen isolates (5.4 %) had an IC50
greater than 60 nM and were considered to display re-
duced susceptibility to pyronaridine in vitro [10]. The re-
duced susceptibility to pyronaridine, defined as IC50 > 60
nM, was significantly associated with the K76T mutation
(p-value = 0.004). The odds ratio for reduced susceptibil-
ity to pyronaridine associated with the K76T mutation
was 4.47 (95 % CI [1.39–18.84]). The in vitro resistance
to chloroquine, defined as IC50 > 100 nM, was also
significantly associated with the K76T mutation (p-value
< 0.001). The odds ratio for reduced susceptibility to
chloroquine associated with the K76T mutation was
96.4 (95 % CI [41.8–244.8]). Using Bayesian mixture
modelling, the 296 pyronaridine IC50values were classi-
fied into three components: component A (IC50 median
15.9 nM), component B (IC50 median 34.2 nM) and
component C (IC50 median 63.3 nM) (Table 1). The pyr-
onaridine medians were significantly different in the
three components (Kruskal-Wallis test, p-value < 0.001).
The proportion of isolates in each group was 59.8 % for
component A, 30.1 % for component B and 10.1 % for
component C. The K76T mutation represented 46.3 %
of the isolates in component A, 47.2 % of the isolates in
component B and 73.3 % of the isolates in component C
(Kruskal-Wallis test, p-value = 0.021).
The results of the present study showed that ex vivo
reduced susceptibility to pyronaridine, i.e., IC50 > 60 nM,
was associated with the K76T mutation in the pfcrt gene.
These ex vivo results are in contrast with the in vitro re-
sults in 23 P. falciparum strains in which the in vitro to
pyronaridine were not associated with pfcrt polymor-
phisms [15]. However, none of the 23 strains showed re-
duced susceptibility to pyronaridine. In 59 field isolates
from Kenya, pyronaridine was more active in vitro
against parasites harbouring the wild-type sequence than
against those harbouring the K76T mutation (IC50 of 6
versus 20 nM). However, this difference was not signifi-
cant (p-value > 0.05) [16]. The odds ratio for the K76T
mutation associated with reduced susceptibility to pyro-
naridine was 4.47, whereas the odds ratio for in vitro re-
sistance to chloroquine was 96.4. The resistance to
pyronaridine is certainly multigenic, and additional poly-
morphisms in other genes could also be involved in this
resistance.
In contrast with piperaquine, in which its in vitro re-
sponses are not associated with pfcrt polymorphism in
isolates from Africa and Asia [13, 14, 17, 18] but rather
associated with repeat polymorphisms in an ABC trans-
porter gene, pfmdr6 [19], pyronaridine mechanisms of
resistance are different than those involved in pipera-
quine. Pyronaridine-artesunate could be used in areas
where resistance to other ACTs has already emerged.
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Pyronaridine-artesunate successfully treats artemisinin-
resistant P. berghei parasites, while artemether-lumefantrine,
artesunate-amodiaquine, artesunate-mefloquine and
dihydroartemisinin-piperaquine are not effective [20].
Pyronaridine-artesunate showed better efficacy than
mefloquine-artesunate for the treatment of uncomplicated
falciparum malaria in Cambodia and a non-inferior efficacy
compared with that of artemether-lumefantrine in Africa
and Southeast Asia [2–4]. Pyronaridine-artesunate showed
greater than 95 % efficacy when used as an initial falciparum
malaria treatment versus the re-treatment of subsequent
episodes in a multi-site trial in Mali, Burkina Faso and
Guinea [21]. In addition, pyronaridine-artesunate is also
affective in the treatment of acute uncomplicated P. vivax
malaria [5]. Pyronaridine-artesunate is an alternative
artemisinin-based combination treatment for malaria in
sub-Saharan Africa.
Ethical approval
According to the French legislation, bio-banking and
secondary use for scientific purposes of human clin-
ical samples are possible as long as the corresponding
Fig. 1 Pyronaridine median and 25 and 75 percentiles of the 50 % inhibitory concentration (IC50 in nM) of 296 African Plasmodium
falciparum isolates
Table 1 Distribution of the IC50 of pyronaridine and chloroquine and the K76T mutation according to the three components
defined by the Bayesian mixture modeling approach
Component A Component B Component C P-value
No of isolates 177 89 30
Pyronaridine median IC50 15.9 nM 34.2 nM 63.3 nM <0.001
Pyronaridine 25 % percentile 11.2 nM 30.4 nM 51.2 nM
Pyronaridine 75 % percentile 18.5 nM 37.1 nM 69.7 nM
Chloroquine median IC50 57.0 nM 90.6 nM 240.5 nM 0.003
Chloroquine 25 % percentile 18.3 nM 19.7 nM 71.2 nM
Chloroquine 75 % percentile 207 nM 273 nM 301 nM
No of K76T mutation (%) 82 (46.3) 42 (47.2) 22 (73.3) 0.021
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patients are informed and have not indicated any ob-
jections. This requirement was fulfilled here since in-
formation is given to every patient through a hospital
notice entitled “Information for Patients,” and no im-
mediate or delayed patient opposition was reported
by the hospital clinicians to the French Malaria Refer-
ence Center. Moreover, samples received at the
French Malaria Reference Center were registered and
declared for research purposes as a bio-bank for the
French National Institute of Health Survey. No insti-
tutional review board approval is required according
to French legislation (article L. 1111–7 du Code de la
Santé Publique, article L. 1211–2 du Code de Santé
Publique, articles 39 et suivants de la loi 78–17 du 6
janvier 1978 modifiée en 2004 relative à l’informa-
tique, aux fichiers, et aux libertés).
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